MedTrace Logo

Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

NCT06224790 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy

Conditions

Interventions

DRUG

Pirfenidone

Capsule Pirfenidone 1200mg/ day in divided doses for 3 months

OTHER

Placebo

2 Capsules 3 times a day for 3 months

Sponsors & Collaborators

  • Sidrah Lodhi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-10
Primary Completion
2025-03-07
Completion
2025-03-07

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06224790 on ClinicalTrials.gov